Mollie Leoni Sells 84,929 Shares of Kura Oncology (NASDAQ:KURA) Stock

Kura Oncology, Inc. (NASDAQ:KURA) insider Mollie Leoni sold 84,929 shares of Kura Oncology stock in a transaction on Thursday, June 18th. The stock was sold at an average price of $9.82, for a total transaction of $834,002.78. Following the completion of the transaction, the insider directly owned 182,345 shares in the company, valued at approximately $1,790,627.90. The trade was a 31.78% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Kura Oncology Trading Up 4.3%

NASDAQ:KURA traded up $0.43 during midday trading on Monday, reaching $10.36. 1,383,021 shares of the stock traded hands, compared to its average volume of 1,581,991. The stock has a market capitalization of $919.66 million, a P/E ratio of -3.09 and a beta of 0.36. The company has a debt-to-equity ratio of 0.09, a quick ratio of 6.14 and a current ratio of 6.15. The company has a fifty day moving average of $9.41 and a 200 day moving average of $9.23. Kura Oncology, Inc. has a 12 month low of $5.45 and a 12 month high of $12.49.

Kura Oncology (NASDAQ:KURA) last announced its quarterly earnings results on Tuesday, May 12th. The company reported ($0.83) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.88) by $0.05. The business had revenue of $18.27 million for the quarter, compared to analyst estimates of $25.97 million. Kura Oncology had a negative net margin of 411.19% and a negative return on equity of 141.95%. On average, research analysts predict that Kura Oncology, Inc. will post -3.47 EPS for the current year.

Institutional Investors Weigh In On Kura Oncology

Large investors have recently modified their holdings of the stock. State Street Corp increased its position in shares of Kura Oncology by 47.5% during the fourth quarter. State Street Corp now owns 4,931,090 shares of the company’s stock valued at $51,234,000 after buying an additional 1,587,959 shares during the period. Jacobs Levy Equity Management Inc. lifted its holdings in Kura Oncology by 101.6% in the third quarter. Jacobs Levy Equity Management Inc. now owns 2,224,590 shares of the company’s stock worth $19,688,000 after buying an additional 1,121,228 shares during the period. Renaissance Technologies LLC lifted its holdings in Kura Oncology by 111.6% in the fourth quarter. Renaissance Technologies LLC now owns 1,830,566 shares of the company’s stock worth $19,020,000 after buying an additional 965,256 shares during the period. AQR Capital Management LLC boosted its position in Kura Oncology by 36.6% during the 4th quarter. AQR Capital Management LLC now owns 3,062,212 shares of the company’s stock valued at $31,816,000 after acquiring an additional 820,020 shares in the last quarter. Finally, Qube Research & Technologies Ltd boosted its position in Kura Oncology by 63.0% during the 2nd quarter. Qube Research & Technologies Ltd now owns 1,911,886 shares of the company’s stock valued at $11,032,000 after acquiring an additional 738,761 shares in the last quarter.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on KURA. Sanford C. Bernstein set a $24.00 price target on Kura Oncology in a report on Monday, June 15th. Wall Street Zen upgraded Kura Oncology from a “strong sell” rating to a “hold” rating in a report on Saturday, May 16th. Citigroup reiterated a “market outperform” rating on shares of Kura Oncology in a research report on Thursday, May 28th. UBS Group reissued a “buy” rating and set a $15.00 target price (down from $16.00) on shares of Kura Oncology in a research note on Friday, March 13th. Finally, Zacks Research upgraded Kura Oncology from a “strong sell” rating to a “hold” rating in a report on Thursday, February 26th. Ten analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Kura Oncology currently has an average rating of “Moderate Buy” and a consensus target price of $25.46.

About Kura Oncology

Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura’s research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.

The company’s lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.